- 40 次围观
产品图片
货号/SKU
NR-55332
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、3
产品描述信息
NR-55332??SARS-Related Coronavirus 2, Isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429)(Viruses)|SARS-Related Coronavirus 2|Isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429)|-60°C or colder|CDCAcknowledgment for publications should read “The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429), NR-55332.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/CA-CDC-50070/2020 [also referred to as NS3 3002228941 H7 (p2) 3dpi] was isolated from a nasopharyngeal aspirate in California, USA on December 23, 2020.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Note: Due to the dynamic nature of lineage determination using PANGO, it is recommended to confirm provided GISAID information prior to initiation of work.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429) is assigned lineage B.1.429 and GISAID clade GH using Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. The complete genome of SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020 has been sequenced [Clinical isolate (referred to as hCoV-19/USA/CA-CDC-2-3921631/2020): GISAID: EPI_ISL_1225966]. The following mutations are present in the clinical isolate: Spike D614G, Spike L452R, Spike S13I, Spike W152C, N (Nucleocapsid protein) R191H, N T205I, ORF3 Q57H, ORF7a E22D, ORF7b H42Y, NSP2 (Non-structural protein 2) T85I, NSP9 (Non-structural protein 9) I65V, NSP12 (Non-structural protein 12) P323L, NSP13 (Non-structural protein 13) D260Y.
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma cells infected with SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/CA-CDC-50070/2020 [also referred to as NS3 3002228941 H7 (p2) 3dpi] was isolated from a nasopharyngeal aspirate in California, USA on December 23, 2020.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Note: Due to the dynamic nature of lineage determination using PANGO, it is recommended to confirm provided GISAID information prior to initiation of work.
Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429) is assigned lineage B.1.429 and GISAID clade GH using Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. The complete genome of SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020 has been sequenced [Clinical isolate (referred to as hCoV-19/USA/CA-CDC-2-3921631/2020): GISAID: EPI_ISL_1225966]. The following mutations are present in the clinical isolate: Spike D614G, Spike L452R, Spike S13I, Spike W152C, N (Nucleocapsid protein) R191H, N T205I, ORF3 Q57H, ORF7a E22D, ORF7b H42Y, NSP2 (Non-structural protein 2) T85I, NSP9 (Non-structural protein 9) I65V, NSP12 (Non-structural protein 12) P323L, NSP13 (Non-structural protein 13) D260Y.
Each vial contains approximately 0.1 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma cells infected with SARS-CoV-2, isolate hCoV-19/USA/CA-CDC-50070/2020.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
从鼻咽吸气中分离出严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2），分离为HCOV-19 / USA / CA-CA-50070/2020 [也称为NS3 3002228941 H7（P2）3DPI]加利福尼亚州，美国于2020年12月23日.
注意：基因组序列信息在分析证书上提供，并且包括对每个批次观察到的所有序列变化的分析.
注意：由于使用Pango的谱系确定的动态性质，建议在开始工作之前确认提供的GISAID信息.
根据GISAID引入的命名系统（全球共享所有流感数据的全球倡议），SARS-COV-2，分离HCOV-19 / USA / CA-CDC-50070/2020（谱系B.1.429）被分配谱系B.1.429和GISAID CLADE GH使用命名的全球爆发谱系（Pango）工具的系统发育分配. SARS-COV-2的完整基因组，分离物HCOV-19 / USA / CA-CDC-50070/2020已经测量[临床分离物（称为HCOV-19 / USA / CA-CA-CDC-2-3921631 / 2020） ：GISAID：EPI_ISL_1225966].以下突变存在于临床分离物中：尖峰D614G，尖峰L452R，尖峰S13i，尖峰W152C，N（核衣壳蛋白）R191H，N T205I，ORF3 Q57H，ORF7A E22D，ORF7B H42Y，NSP2（非结构蛋白2）T85I ，NSP9（非结构蛋白9）I65V，NSP12（非结构蛋白12）P323L，NSP13（非结构蛋白13）D260Y.
每个小瓶含有大约0.1ml的旋转澄清的细胞裂解物和来自 Homo sapiens的上清液用SARS-COV-2感染的肺腺癌细胞，分离HCOV-19 / USA / CA-CDC-50070/2020.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2024-01-21
2022-04-01
2024-01-21
2021-12-02
2022-04-01
2022-04-01
2022-04-01
2024-01-21
2024-01-21
2021-12-21
2022-03-31
2022-04-01
2022-04-01
2022-06-17